Horizon Pharma to pay $65 million in settlement with Express Scripts

30 September 2016
medical_legal_law_big

Ireland-based drugmaker Horizon Pharma (Nasdaq: HZNP) saw its share price drop by more than 5% in a day following news that it will pay US pharmacy benefit manager Express Scripts $65 million to settle rebate litigation.

Express Scripts had initially asked for $166.2 million as it took legal action in November of last year against the Dublin-based company for alleged after-market rebates for three of its medicines.

These were Rayos (prednisone), a rheumatology treatment, along with pain relief products Duexis (ibuprofen/famotidine) and Vimovo (naproxen/esomeprazole magnesium).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical